Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer

Kramer,Mario K.; Waalkes,Sandra; Hennenlotter,Jörg; Serth,Jürgen; Stenzl,Arnulf; Kuczyk,Markus A.; Merseburger,Axel S.

doi:10.3892/ol_00000110

Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer

Authors:
- Mario K. Kramer
- Sandra Waalkes
- Jörg Hennenlotter
- Jürgen Serth
- Arnulf Stenzl
- Markus A. Kuczyk
- Axel S. Merseburger
View Affiliations

Affiliations: Department of Urology, Hannover Medical School, D-30625 Hannover, Germany
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000110
Pages: 621-626

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Maspin is a 42-kDa protein that belongs to the family of serine protease inhibitors. It is involved in various physiological processes. In cancer tissue, Maspin was found to influence angiogenesis, tumor growth, metastasis and the prognosis of tumor patients. This study was performed to analyze the involvement of Maspin in transitional cell carcinoma of the bladder as well as its prognostic impact in a large patient cohort. Specimens from 162 non-muscle invasive bladder cancer patients (pTa, 91; pT1, 71) treated by transurethral resection with a minimum 3-year follow-up (median 58.5 months) were included in the present investigation. Tissue microarrays were constructed, and the specimens were immunohistochemically stained for Maspin protein expression. Each tissue specimen was assessed on a staining scale ranging from 0 (no staining) to 300 (strong staining) and correlated with various clinicopathological parameters. Maspin protein expression predicted progression with a sensitivity of 95% and a specificity of 70% (p<0.001). In predicting recurrence, Maspin staining showed 52% sensitivity and 67% specificity (p<0.05). Kaplan-Meier analyses were performed, and a low Maspin protein expression was correlated with a higher incidence of tumor progression (p<0.0001). However, expression levels of Maspin protein did not distinguish between pTa and pT1 specimens. Multivariate analyses indicated Maspin expression as an independent factor for predicting progression (p<0.0001) and recurrence (p<0.05). The present results suggest that the Maspin protein expression is an independent prognostic indicator for predicting recurrence and progression to muscle invasive disease. This study further emphasizes a possible clinical role of this novel tumor suppressor gene in transitional cell carcinoma of the bladder.

View Figures

View References

1	Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin. 49:8–31. 1999.
2	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin. 59:225–249. 2009.
3	Guney S, Guney N, Canogullari Z and Ergenekon E: TaT1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year. Urol Int. 80:124–128. 2008.PubMed/NCBI
4	Holmang S, Hedelin H, Anderstrom C, Holmberg E, Busch C and Johansson SL: Recurrence and progression in low grade papillary urothelial tumors. J Urol. 162:702–707. 1999. View Article : Google Scholar : PubMed/NCBI
5	Herr HW: Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 163:60–62. 2000.PubMed/NCBI
6	Futscher BW, Oshiro MM, Wozniak RJ, et al: Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet. 31:175–179. 2002. View Article : Google Scholar : PubMed/NCBI
7	Gao F, Shi HY, Daughty C, Cella N and Zhang M: Maspin plays an essential embryonic development. Development. 131:1479–1489. 2004. View Article : Google Scholar : PubMed/NCBI
8	Zhang M, Volpert O, Shi YH and Bouck N: Maspin is an angiogenesis inhibitor. Nat Med. 6:196–199. 2000. View Article : Google Scholar
9	Odero-Marah VA, Khalkhali-Ellis Z, Chunthapong J, et al: Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther. 2:398–403. 2003. View Article : Google Scholar : PubMed/NCBI
10	McGowen R, Biliran H Jr, Sager R and Sheng S: The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res. 60:4771–4778. 2000.PubMed/NCBI
11	Jiang N, Meng Y, Zhang S, Mensah-Osman E and Sheng S: Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene. 21:4089–4098. 2002. View Article : Google Scholar : PubMed/NCBI
12	Lockett J, Yin S, Li X, Meng Y and Sheng S: Tumor suppressive maspin and epithelial homeostasis. J Cell Biochem. 97:651–660. 2006. View Article : Google Scholar : PubMed/NCBI
13	Beecken WD, Engl T, Engels K, et al: Clinical relevance of maspin expression in bladder cancer. World J Urol. 24:338–344. 2006. View Article : Google Scholar : PubMed/NCBI
14	Sugimoto S, Maass N, Takimoto Y, et al: Expression and regulation of tumor suppressor gene maspin in human bladder cancer. Cancer Lett. 203:209–215. 2004. View Article : Google Scholar : PubMed/NCBI
15	Friedrich MG, Toma MI, Petri S, et al: Expression of maspin in non-muscle invasive bladder carcinoma: Correlation with tumor angiogenesis and prognosis. Eur Urol. 45:737–743. 2004. View Article : Google Scholar : PubMed/NCBI
16	Blandamura S, D’Alessandro E, Giacomelli L, et al: Expression of maspin in papillary Ta/T1 bladder neoplasms. Anticancer Res. 28:471–478. 2008.PubMed/NCBI
17	Kramer MW, Kuczyk MA, Hennenlotter J, et al: Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. Oncol Rep. 20:1403–1408. 2008.PubMed/NCBI
18	Mostofi FK, Sorbin L and Torloni H: Histological typing of urinary bladder tumours International classification of tumours. World Health Organisation. Geneva: 1973.
19	Kramer MW, Merseburger AS, Hennenlotter J and Kuczyk M: Tissue microarrays in clinical urology – technical considerations. Scand J Urol Nephrol. 41:478–484. 2007.
20	Merseburger AS, Anastasiadis AG, Hennenlotter J, et al: Tissue microarrays: applications in urological cancer research. World J Urol. 24:579–584. 2006. View Article : Google Scholar : PubMed/NCBI
21	Merseburger AS, Kramer MW, Hennenlotter J, et al: Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol. 26:637–642. 2008. View Article : Google Scholar : PubMed/NCBI
22	Ngamkitidechakul C, Burke JM, O’Brien WJ and Twining SS: Maspin: synthesis by human cornea and regulation of in vitro stromal cell adhesion to extracellular matrix. Invest Ophthalmol Vis Sci. 42:3135–3141. 2001.PubMed/NCBI
23	Reis-Filho JS, Milanezi F, Silva P and Schmitt FC: Maspin expression in myoepithelial tumors of the breast. Pathol Res Pract. 197:817–821. 2001. View Article : Google Scholar : PubMed/NCBI
24	Reis-Filho JS, Torio B, Albergaria A and Schmitt FC: Maspin expression in normal skin and usual cutaneous carcinomas. Virchows Arch. 441:551–558. 2002. View Article : Google Scholar : PubMed/NCBI
25	Mohsin SK, Zhang M, Clark GM and Craig Allred D: Maspin expression in invasive breast cancer: Association with other prognostic factors. J Pathol. 199:432–435. 2003. View Article : Google Scholar : PubMed/NCBI
26	Sood AK, Fletcher MS, Gruman LM, et al: The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 8:2924–2932. 2002.PubMed/NCBI
27	Heighway J, Knapp T, Boyce L, et al: Expression profiling of primary non-small cell lung cancer for target identification. Oncogene. 21:7749–7763. 2002. View Article : Google Scholar : PubMed/NCBI